Take the plunge

Visit the **Alhemo™ Product Theatre** to learn how Alhemo™ can support your haemophilia B patients with inhibitors[1]

Alhemo™ is the first subcutaneous prophylactic treatment for patients with haemophilia B with inhibitors, delivered with a first-in-class prefilled pen device.[1]

June 25th 2023 | 12:15–13:00 (EST)

Presentation Theatre 4

AGENDA

12:15	**Welcome and introduction**	Dr. Stephanie Seremetis
12:20	**What are the remaining unmet needs in haemophilia B with inhibitors?**	Dr. Manuel Carcao
12:30	**Bringing innovation in the treatment of haemophilia B with inhibitors**	Dr. Stephanie Seremetis
12:50	**Holistically addressing patient convenience with a new pen device**	Vanessa Bouskill
13:00	**Meeting closure**	All

SPEAKERS

Dr. Stephanie Seremetis
CVP and Chief Medical Officer
Rare Disease and Advanced Therapies,
Novo Nordisk, Bagsvaerd, Denmark

Dr. Manuel Carcao
Hospital for Sick Children,
Toronto, Ontario, Canada

Vanessa Bouskill
Hospital for Sick Children,
Toronto, Ontario, Canada

The image shown is a model and not a real patient.

novo nordisk®

The information presented is based on the Canadian label. Alhemo™ is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding in patients ≥ 12 years of age with haemophilia B (congenital factor IX deficiency) with factor IX inhibitors.[1]

Pr Alhemo™
concizumab

Everyday protection for your haemophilia B patients with inhibitors (HBwI)[1]

1st subcutaneous prophylaxis for HBwI[1]

Mean ABR of 1.7 for patients with inhibitors in the explorer 7 trial[1]

1st in class pen[1]

Prefilled, portable pen that can be stored at room temperature*[1]

Established safety profile[1]

Well-tolerated and can be used concomitantly with both bypassing agents†[1]

Indications:

Alhemo™ (concizumab injection) is indicated for the treatment of adolescent and adult patients (12 years of age or older) with haemophilia B (congenital factor IX [FIX] deficiency) who have FIX inhibitors and require routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

There is limited clinical experience of Alhemo™ use in patients known to have mild or moderate haemophilia B (FIX activity > 2%).

Please visit https://www.novonordisk.ca/content/dam/nncorp/ca/en/products/alhemo-en-product-monograph.pdf for more information relating to adverse reactions, drug interactions, and dosing information, which have not been discussed in this advertisement. The Product Monograph is also available by calling us at 1-800-465-4334.

The information presented is based on the Canadian label. This material is intended to be used at the ISTH 2023 Congress only.

* Up to 30 °C for up to 4 weeks.
† For both bypassing agents, the lowest approved dose and dosing interval in the approved label are recommended. For activated prothrombin complex concentrate (aPCC), a maximum dose of 100 international unit/kg body weight within 24 hours is recommended. For severe bleeds, it is recommended to follow the dosing interval provided in the approved label for each product, based on clinical judgement.[1]

Reference: 1. Novo Nordisk Canada Inc. Alhemo™ Product Monograph. March 10, 2023. Available at: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102487.

CA23AHM00013

Pr Alhemo™ concizumab